Gauge and Scheme Dependence of Mixing Matrix Renormalization

We revisit the issue of mixing matrix renormalization in theories that include Dirac or Majorana fermions. We show how a gauge-variant on-shell renormalized mixing matrix can be related to a manifestly gauge-independent one within a generalized ${\bar {\rm MS}}$ scheme of renormalization. This scheme-dependent relation is a consequence of the fact that in any scheme of renormalization, the gauge-dependent part of the mixing-matrix counterterm is ultra-violet safe and has a pure dispersive form. Employing the unitarity properties of the theory, we can successfully utilize the afore-mentioned scheme-dependent relation to preserve basic global or local symmetries of the bare Lagrangian through the entire process of renormalization. As an immediate application of our study, we derive the gauge-independent renormalization-group equations of mixing matrices in a minimal extension of the Standard Model with isosinglet neutrinos.Comment: 31 pages, LaTeX, uses axodraw.st

Realism and illusion in Americans' temporal views of their life satisfaction: age differences in reconstructing the past and anticipating the future

We examined actual and perceived trajectories of change in life satisfaction in a national sample of 3,793 adults, ages 24 to 74 at baseline, who provided retrospective, present, and prospective ratings on two occasions 8 to 10 years apart. There was little actual change in satisfaction ratings, but there were age differences in anticipated change, with young adults expecting things to improve and older adults expecting decline. When we compared the actual (present) ratings with corresponding past or future ratings, older adults showed more temporal realism (retrospective and anticipatory ratings matched actual levels) than did young and middle-aged adults; in other words, young and middle-aged adults showed greater illusion (retrospective and prospective ratings overestimated or underestimated actual levels). At all ages, however, temporal realism was associated with more adaptive current functioning than was illusion. We discuss these findings from a life-span developmental perspective on motivational shifts from growth to maintenance and consider the implications of accuracy in evaluating the past and future

The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

open14sifunding from Boehringer Ingelheim.GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non-vitamin K antagonist oral anticoagulant (NOAC), became available. OBJECTIVES: This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. METHODS: During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients' baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. RESULTS: Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score ≥2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. CONCLUSIONS: The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701)openHuisman, Mv; Rothman, Kj; Paquette, M; Teutsch, C; Diener, Hc; Dubner, Sj; Halperin, Jl; Ma, Cs; Zint, K; Elsaesser, A; Bartels, Db; Lip, Gy; GLORIA-AF, Investigators; Diemberger, I.Huisman, Mv; Rothman, Kj; Paquette, M; Teutsch, C; Diener, Hc; Dubner, Sj; Halperin, Jl; Ma, Cs; Zint, K; Elsaesser, A; Bartels, Db; Lip, Gy; GLORIA-AF, Investigators; Diemberger, I